Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OptiNose, Inc.
With positive Phase III data for its Xhance (fluticasone propionate) nasal spray in chronic sinusitis, Optinose believes it is poised to expand the target market for the drug 10-fold.
The latest drug development news and highlights from our US FDA Performance Tracker.
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
- Medical Devices
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- OptiNose AS
- OptiNose UK Ltd.
- OptiNose US, Inc.